This is supported by reports that increased production of the IL-4 antagonist IL-4δ2 is seen in individuals who are controlling TB in its latent stage [20] and that the IL-4δ2 /IL-4 ratio increases during treatment of TB patients [25] and in those TB patients who respond most rapidly to therapy [84]. Here, IL4 is linked to tuberculosis.